Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 15/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1553935 | 0.79 | ADORA1 (0.63) | ADORA2AADORA1ADORA2BPDE3BPDE3A | |
| SCHEMBL1554139 | 0.72 | ADORA2A (0.54) | ADORA2AADORA1ADORA2BDHFR | |
| SCHEMBL7149019 | 0.70 | ADORA2A (0.46) | ADORA2AADORA1ADORA2BDHFR | |
| SCHEMBL3456558 | 0.70 | ADORA1 (0.57) | ADORA2AADORA1ADORA2BPDE3BPDE3A | |
| SCHEMBL6133799 | 0.69 | ADORA2A (0.54) | ADORA2AADORA1ADORA2BADORA3PDE3B | |
| SCHEMBL7144400 | 0.69 | ADORA2A (0.50) | ADORA2AADORA1ADORA2BDHFR | |
| SCHEMBL4330714 | 0.67 | ADORA2A (0.57) | ADORA2AADORA1ADORA2B | |
| SCHEMBL7147816 | 0.66 | ADORA2A (0.52) | ADORA2AADORA1ADORA2BADORA3DHFR | |
| SCHEMBL7144862 | 0.66 | ADORA2A (0.50) | ADORA2AADORA1ADORA2BDHFR | |
| SCHEMBL30353572 | 0.66 | ADORA2A (0.52) | ADORA2AADORA1ADORA2BDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111986-A1 | NOVEL CRYSTALS OF PYRIMIDINE COMPOUND AND PROCESS FOR PRODUCING THE SAME | HARADA HITOSHI | 2009-04-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111986-A1 | NOVEL CRYSTALS OF PYRIMIDINE COMPOUND AND PROCESS FOR PRODUCING THE SAME | UMPS, P2RX5, APC | ADORA2A 332/4885ADORA1 203/4885ADORA2B 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.